Globus Medical Q2 EPS beats estimates by 21.82% on margin expansion
Globus Medical delivered strong Q2FY26 results with adjusted EPS of $1.34 beating estimates by 21.82%. Sales grew 5.9% to $789.6 million, driven by US and International Spine gains. The company raised full-year EPS guidance.
*this image is generated using AI for illustrative purposes only.
Globus Medical (NYSE: GMED) delivered a robust second quarter performance in FY26, reporting non-GAAP diluted earnings per share of $1.34, which significantly exceeded analyst consensus estimates of $1.10. The musculoskeletal technology company also saw worldwide net sales rise 5.9% year-over-year to $789.6 million, driven by strong share gains in its US Spine and International Spine businesses. These results underscore effective cost management and margin expansion, leading the firm to raise its full-year non-GAAP EPS guidance to a range of $4.95 to $5.05.
The earnings beat of 21.82% highlights operational leverage realized during the period, while the revenue beat of 0.87% against an estimated $782.8 million indicates sustained market demand. Compared to the prior year, adjusted EPS surged by 55.8% from $0.86, reflecting a substantial improvement in profitability. Revenue grew from $745.3 million in the corresponding quarter last year, demonstrating consistent organic growth despite currency headwinds that resulted in a 5.6% constant currency growth rate.
Financial Highlights
| Metric | Actual | Estimate | Variance | YoY Change |
|---|---|---|---|---|
| Adjusted EPS | $1.34 | $1.10 | +21.82% | +55.8% |
| Sales | $789.6 million | $782.8 million | +0.87% | +5.9% |
| GAAP Net Income | $151.6 million | N/A | N/A | -25.3% |
The company’s ability to exceed both earnings and revenue estimates suggests strong market positioning. The significant year-over-year jump in EPS points to improved underlying profitability drivers, even as GAAP net income decreased by 25.3% to $151.6 million, primarily due to a $110.5 million bargain purchase gain recognized in the prior year related to the Nevro acquisition.
Segment Performance and Guidance
US Spine led organizational growth for the fifth consecutive quarter, with US net sales increasing by 3.0% compared to the second quarter of 2025. International net sales showed stronger momentum, rising 18.0% on an as-reported basis and 16.2% on a constant currency basis. Keith Pfeil, President and Chief Executive Officer, noted that share gains across underlying businesses drove the 9% growth excluding Nevro.
Kyle Kline, Chief Financial Officer, attributed the record second-quarter non-GAAP net income to broad-based growth paired with adjusted gross margin expansion of 200 basis points compared to the prior year quarter. The Company reaffirmed its full-year 2026 revenue guidance of $3.18 billion to $3.22 billion but updated its non-GAAP fully diluted EPS guidance upward from the previous range of $4.70 to $4.80.
What the Numbers Show
The divergence between the modest revenue beat (0.87%) and the substantial earnings beat (21.82%) suggests that Globus Medical benefited disproportionately from margin expansion rather than just volume growth. While sales grew steadily at 5.9% year-over-year, the 55.8% surge in adjusted EPS indicates that operating efficiencies or favorable mix shifts played a critical role in boosting bottom-line results. This pattern implies that management has successfully optimized costs or product mix to drive higher profitability even as top-line growth remains moderate.
How sustainable is the 200 basis point gross margin expansion, and what specific operational levers is Globus Medical prioritizing to maintain this profitability trajectory in FY26?
Given the strong momentum in International Spine sales (18.0% growth), which specific geographic regions or emerging markets are driving this acceleration, and how might currency fluctuations impact future constant currency growth?
With US Spine share gains continuing for five consecutive quarters, what competitive strategies or product innovations are enabling Globus to capture market share from larger incumbents in the domestic spine segment?
20
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
